ArticleJournal for immunotherapy of cancer2024

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).

Diwakar Davar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.